Table 2.
Procedural details according to device
| Variables | Total population (177) | Edwards SAPIEN (126) |
Medtronic CoreValve (51) | p Value |
|---|---|---|---|---|
| Preventive PCI pre-TAVI, n (%) | 24 (13.6%) | 17 (13.5%) | 7 (13.7%) | 0.99 |
| Iliac PTA before TAVI, n (%) | 15 (8.5%) | 8 (6.3%) | 7 (13.7%) | 0.14 |
| PCI during TAVI, n (%) | 6 (3.4%) | 3 (2.4%) | 3 (5.9%) | 0.54 |
| Valvular pathology, n (%) | ||||
| AS | 142 (80%) | 115 (91.3%) | 27 (52.9%) | |
| AS+AR | 25 (14.1%) | 8 (6.3%) | 17 (33.3%) | |
| Degenerated aortic prosthesis (VIV) | 10 (5.6%) | 3 (2.4%) | 7 (13.7%) | |
| Prosthesis size, n (%) | ||||
| 20 mm | 1 (0.6%) | 1 (0.8%) | 0 | |
| 23 mm | 56 (31.6%) | 51 (40.5%) | 5 (9.8%) | |
| 26 mm | 74 (41.8%) | 61 (48.4%) | 13 (25.5%) | |
| 29 mm | 38 (21.5%) | 13 (10.3%) | 25 (49%) | |
| 31 mm | 8 (4.5%) | 0 | 8 (15.7%) | |
| Balloon post dilation, n (%) | 13 (7.3%) | 4 (3.2%) | 9 (17.6%) | 0.002 |
| Conversion to heart surgery, n (%) | 0 | 0 | 0 | |
| Death during procedure, n (%) | 0 | 0 | 0 | |
| VARC-2 device non-success, n (%) | 6 (3.4%) | 4 (3.2%) | 2 (3.9%) | 0.99 |
AR, aortic regurgitation; AS, aortic stenosis; PCI, percutaneous coronary intervention; PTA, percutaneous transluminal angioplasty; VARC-2, Valve Academic Research Consortium; VIV, valve in valve.